schliessen

Filtern

 

Bibliotheken

Cover Image

Reinventing clinical trials

The escalating expenses associated with clinical work are so ruinous, an industry that is renowned for sticking to the status quo is considering making extraordinary changes to the way it goes about R&D. The issue goes even beyond clinical trials. The old way of doing biomedical research and drug R&... Full description

Journal Title: Nature biotechnology 2012, Vol.30 (1), p.41-49
Main Author: ALLISON, Malorye
Format: Electronic Article Electronic Article
Language: English
Subjects:
Automatic Data Processing - methods
Biological and medical sciences
Biomedical research
Biotechnology
Clinical trials
Clinical Trials, Phase II as Topic - economics
Clinical Trials, Phase II as Topic - standards
Clinical Trials, Phase II as Topic - trends
Clinical Trials, Phase III as Topic - economics
Clinical Trials, Phase III as Topic - standards
Clinical Trials, Phase III as Topic - trends
Drug Approval - statistics & numerical data
Drug Industry
Efficiency
Fundamental and applied biological sciences. Psychology
General pharmacology
Humans
Legislation. General informations
Medical sciences
National Cancer Institute (U.S.)
Pharmaceutical technology. Pharmaceutical industry
Pharmacology
Pharmacology. Drug treatments
R&D
Research & development
Safety - standards
Technology, Pharmaceutical - economics
Technology, Pharmaceutical - trends
United States
United States Food and Drug Administration
Publisher: New York, NY: Nature Publishing Group
ID: ISSN: 1087-0156
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_915381602
title: Reinventing clinical trials
format: Article
creator:
  • ALLISON, Malorye
subjects:
  • Automatic Data Processing - methods
  • Biological and medical sciences
  • Biomedical research
  • Biotechnology
  • Clinical trials
  • Clinical Trials, Phase II as Topic - economics
  • Clinical Trials, Phase II as Topic - standards
  • Clinical Trials, Phase II as Topic - trends
  • Clinical Trials, Phase III as Topic - economics
  • Clinical Trials, Phase III as Topic - standards
  • Clinical Trials, Phase III as Topic - trends
  • Drug Approval - statistics & numerical data
  • Drug Industry
  • Efficiency
  • Fundamental and applied biological sciences. Psychology
  • General pharmacology
  • Humans
  • Legislation. General informations
  • Medical sciences
  • National Cancer Institute (U.S.)
  • Pharmaceutical technology. Pharmaceutical industry
  • Pharmacology
  • Pharmacology. Drug treatments
  • R&D
  • Research & development
  • Safety - standards
  • Technology, Pharmaceutical - economics
  • Technology, Pharmaceutical - trends
  • United States
  • United States Food and Drug Administration
ispartof: Nature biotechnology, 2012, Vol.30 (1), p.41-49
description: The escalating expenses associated with clinical work are so ruinous, an industry that is renowned for sticking to the status quo is considering making extraordinary changes to the way it goes about R&D. The issue goes even beyond clinical trials. The old way of doing biomedical research and drug R&D are not feasible anymore. That realization is leading to a startling revamp of the clinical trial process.
language: eng
source:
identifier: ISSN: 1087-0156
fulltext: no_fulltext
issn:
  • 1087-0156
  • 1546-1696
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5405748
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_915381602
sourceformatXML
sourcesystemPC
sourcerecordid2635524301
originalsourceidFETCH-LOGICAL-1388t-f7292ff7c77f1fbc499574173f745708f0b1da4aa5067fcbf40f1eb189c3df4d0
addsrcrecordideNpl0EtLAzEUBeAgiq1VcC9IQUQ3U28ek2SWUnxBQRBdD5k0kZRppiYZwX9vSqtCJYubxcc9l4PQKYYJBipvfJMmBCTdQ0NcMl5gXvH9_AcpCsAlH6CjGBcAwBnnh2hACKEYKjpEZy_G-U_jk_PvY90677Rqxyk41cZjdGDzMCfbOUJv93ev08di9vzwNL2dFZhKmQorSEWsFVoIi22jWVWVgmFBrWClAGmhwXPFlCqBC6sby8Bi02BZaTq3bA4jdLXZuwrdR29iqpcuatO2ypuuj3WFSyoxB5LlxY5cdH3w-bgaA-D8JBVZXW-UDl2Mwdh6FdxSha-M6nVfde6rXveV6fl2Yd8szfwX_hSUweUWqJibsUF57eKfK5kgHNaZk51M7ZJKrvMpKNf-T_4Gsyl_tA
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1001010837
display
typearticle
titleReinventing clinical trials
creatorALLISON, Malorye
creatorcontribALLISON, Malorye
descriptionThe escalating expenses associated with clinical work are so ruinous, an industry that is renowned for sticking to the status quo is considering making extraordinary changes to the way it goes about R&D. The issue goes even beyond clinical trials. The old way of doing biomedical research and drug R&D are not feasible anymore. That realization is leading to a startling revamp of the clinical trial process.
identifier
0ISSN: 1087-0156
1EISSN: 1546-1696
2DOI: 10.1038/nbt.2083
3PMID: 22231093
4CODEN: NABIF9
languageeng
publisherNew York, NY: Nature Publishing Group
subjectAutomatic Data Processing - methods ; Biological and medical sciences ; Biomedical research ; Biotechnology ; Clinical trials ; Clinical Trials, Phase II as Topic - economics ; Clinical Trials, Phase II as Topic - standards ; Clinical Trials, Phase II as Topic - trends ; Clinical Trials, Phase III as Topic - economics ; Clinical Trials, Phase III as Topic - standards ; Clinical Trials, Phase III as Topic - trends ; Drug Approval - statistics & numerical data ; Drug Industry ; Efficiency ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; Humans ; Legislation. General informations ; Medical sciences ; National Cancer Institute (U.S.) ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology ; Pharmacology. Drug treatments ; R&D ; Research & development ; Safety - standards ; Technology, Pharmaceutical - economics ; Technology, Pharmaceutical - trends ; United States ; United States Food and Drug Administration
ispartofNature biotechnology, 2012, Vol.30 (1), p.41-49
rights
02015 INIST-CNRS
1Copyright Nature Publishing Group Jan 2012
lds50peer_reviewed
citedbyFETCH-LOGICAL-1388t-f7292ff7c77f1fbc499574173f745708f0b1da4aa5067fcbf40f1eb189c3df4d0
citesFETCH-LOGICAL-1388t-f7292ff7c77f1fbc499574173f745708f0b1da4aa5067fcbf40f1eb189c3df4d0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25472607$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22231093$$D View this record in MEDLINE/PubMed
search
creatorcontribALLISON, Malorye
title
0Reinventing clinical trials
1Nature biotechnology
addtitleNat Biotechnol
descriptionThe escalating expenses associated with clinical work are so ruinous, an industry that is renowned for sticking to the status quo is considering making extraordinary changes to the way it goes about R&D. The issue goes even beyond clinical trials. The old way of doing biomedical research and drug R&D are not feasible anymore. That realization is leading to a startling revamp of the clinical trial process.
subject
0Automatic Data Processing - methods
1Biological and medical sciences
2Biomedical research
3Biotechnology
4Clinical trials
5Clinical Trials, Phase II as Topic - economics
6Clinical Trials, Phase II as Topic - standards
7Clinical Trials, Phase II as Topic - trends
8Clinical Trials, Phase III as Topic - economics
9Clinical Trials, Phase III as Topic - standards
10Clinical Trials, Phase III as Topic - trends
11Drug Approval - statistics & numerical data
12Drug Industry
13Efficiency
14Fundamental and applied biological sciences. Psychology
15General pharmacology
16Humans
17Legislation. General informations
18Medical sciences
19National Cancer Institute (U.S.)
20Pharmaceutical technology. Pharmaceutical industry
21Pharmacology
22Pharmacology. Drug treatments
23R&D
24Research & development
25Safety - standards
26Technology, Pharmaceutical - economics
27Technology, Pharmaceutical - trends
28United States
29United States Food and Drug Administration
issn
01087-0156
11546-1696
fulltextfalse
rsrctypearticle
creationdate2012
recordtypearticle
recordideNpl0EtLAzEUBeAgiq1VcC9IQUQ3U28ek2SWUnxBQRBdD5k0kZRppiYZwX9vSqtCJYubxcc9l4PQKYYJBipvfJMmBCTdQ0NcMl5gXvH9_AcpCsAlH6CjGBcAwBnnh2hACKEYKjpEZy_G-U_jk_PvY90677Rqxyk41cZjdGDzMCfbOUJv93ev08di9vzwNL2dFZhKmQorSEWsFVoIi22jWVWVgmFBrWClAGmhwXPFlCqBC6sby8Bi02BZaTq3bA4jdLXZuwrdR29iqpcuatO2ypuuj3WFSyoxB5LlxY5cdH3w-bgaA-D8JBVZXW-UDl2Mwdh6FdxSha-M6nVfde6rXveV6fl2Yd8szfwX_hSUweUWqJibsUF57eKfK5kgHNaZk51M7ZJKrvMpKNf-T_4Gsyl_tA
startdate2012
enddate2012
creatorALLISON, Malorye
generalNature Publishing Group
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
93V.
107QO
117QP
127QR
137T7
147TK
157TM
167X7
177XB
1888A
1988E
2088I
218AO
228FD
238FE
248FG
258FH
268FI
278FJ
288FK
298G5
30ABJCF
31ABUWG
32AZQEC
33BBNVY
34BENPR
35BGLVJ
36BHPHI
37C1K
38DWQXO
39FR3
40FYUFA
41GHDGH
42GNUQQ
43GUQSH
44HCIFZ
45K9.
46L6V
47LK8
48M0S
49M1P
50M2O
51M2P
52M7P
53M7S
54MBDVC
55P64
56PADUT
57PQEST
58PQQKQ
59PQUKI
60PRINS
61PTHSS
62Q9U
63RC3
647X8
sort
creationdate2012
titleReinventing clinical trials
authorALLISON, Malorye
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1388t-f7292ff7c77f1fbc499574173f745708f0b1da4aa5067fcbf40f1eb189c3df4d0
rsrctypearticles
prefilterarticles
languageeng
creationdate2012
topic
0Automatic Data Processing - methods
1Biological and medical sciences
2Biomedical research
3Biotechnology
4Clinical trials
5Clinical Trials, Phase II as Topic - economics
6Clinical Trials, Phase II as Topic - standards
7Clinical Trials, Phase II as Topic - trends
8Clinical Trials, Phase III as Topic - economics
9Clinical Trials, Phase III as Topic - standards
10Clinical Trials, Phase III as Topic - trends
11Drug Approval - statistics & numerical data
12Drug Industry
13Efficiency
14Fundamental and applied biological sciences. Psychology
15General pharmacology
16Humans
17Legislation. General informations
18Medical sciences
19National Cancer Institute (U.S.)
20Pharmaceutical technology. Pharmaceutical industry
21Pharmacology
22Pharmacology. Drug treatments
23R&D
24Research & development
25Safety - standards
26Technology, Pharmaceutical - economics
27Technology, Pharmaceutical - trends
28United States
29United States Food and Drug Administration
toplevelpeer_reviewed
creatorcontribALLISON, Malorye
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8ProQuest Central (Corporate)
9Biotechnology Research Abstracts
10Calcium & Calcified Tissue Abstracts
11Chemoreception Abstracts
12Industrial and Applied Microbiology Abstracts (Microbiology A)
13Neurosciences Abstracts
14Nucleic Acids Abstracts
15Health & Medical Collection
16ProQuest Central (purchase pre-March 2016)
17Biology Database (Alumni Edition)
18Medical Database (Alumni Edition)
19Science Database (Alumni Edition)
20ProQuest Pharma Collection
21Technology Research Database
22ProQuest SciTech Collection
23ProQuest Technology Collection
24ProQuest Natural Science Collection
25Hospital Premium Collection
26Hospital Premium Collection (Alumni Edition)
27ProQuest Central (Alumni) (purchase pre-March 2016)
28Research Library (Alumni Edition)
29Materials Science & Engineering Collection
30ProQuest Central (Alumni Edition)
31ProQuest Central Essentials
32Biological Science Collection
33ProQuest Central
34Technology Collection
35Natural Science Collection
36Environmental Sciences and Pollution Management
37ProQuest Central Korea
38Engineering Research Database
39Health Research Premium Collection
40Health Research Premium Collection (Alumni)
41ProQuest Central Student
42Research Library Prep
43SciTech Premium Collection
44ProQuest Health & Medical Complete (Alumni)
45ProQuest Engineering Collection
46ProQuest Biological Science Collection
47Health & Medical Collection (Alumni Edition)
48Medical Database
49Research Library
50Science Database
51Biological Science Database
52Engineering Database
53Research Library (Corporate)
54Biotechnology and BioEngineering Abstracts
55Research Library China
56ProQuest One Academic Eastern Edition
57ProQuest One Academic
58ProQuest One Academic UKI Edition
59ProQuest Central China
60Engineering Collection
61ProQuest Central Basic
62Genetics Abstracts
63MEDLINE - Academic
jtitleNature biotechnology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
auALLISON, Malorye
formatjournal
genrearticle
ristypeJOUR
atitleReinventing clinical trials
jtitleNature biotechnology
addtitleNat Biotechnol
date2012
risdate2012
volume30
issue1
spage41
epage49
pages41-49
issn1087-0156
eissn1546-1696
codenNABIF9
abstractThe escalating expenses associated with clinical work are so ruinous, an industry that is renowned for sticking to the status quo is considering making extraordinary changes to the way it goes about R&D. The issue goes even beyond clinical trials. The old way of doing biomedical research and drug R&D are not feasible anymore. That realization is leading to a startling revamp of the clinical trial process.
copNew York, NY
pubNature Publishing Group
pmid22231093
doi10.1038/nbt.2083